Deutsche Märkte schließen in 8 Stunden 21 Minuten

AstraZeneca PLC (AZN.L)

LSE - LSE Verzögerter Preis. Währung in GBp (0.01 GBP)
Zur Watchlist hinzufügen
11.166,00+106,00 (+0,96%)
Ab 06:45PM GMT. Markt geöffnet.

AstraZeneca PLC

1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
44 20 3749 5000
https://www.astrazeneca.com

Sektor(en)Healthcare
BrancheDrug Manufacturers—General
Vollzeitmitarbeiter83.100

Leitende Angestellte

NameTitelZahlenAusgeübtGeburtsjahr
Mr. Pascal Soriot D.V.M., M.B.A.CEO & Exec. Director4,75MN/A1959
Dr. Aradhana Sarin M.D.CFO & Exec. Director3,51MN/A1975
Mr. Marc DunoyerCEO of Alexion & Chief Strategy Officer1,66MN/A1952
Ms. Pam P. ChengEVP of Operations & Information Technology and Member of External Sustainability Advisory BoardN/AN/A1971
Mr. Chris SheldonHead of Investor RelationsN/AN/AN/A
Mr. Jeffrey PottChief HR Officer, Gen. Counsel & Member of External Sustainability Advisory BoardN/AN/AN/A
Ms. Katarina AgeborgEVP of Sustainability, Chief Compliance Officer & Member of External Sustainability Advisory BoardN/AN/AN/A
Gonzalo VinaHead of Global Media RelationsN/AN/AN/A
Dr. Menelas Pangalos Ph.D.EVP of BioPharmaceuticals R&D and Member of External Sustainability Advisory BoardN/AN/A1967
Dr. Ruud Dobber Ph.D.Exec. Vice-Pres of BioPharmaceuticals Bus. UnitN/AN/AN/A
Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in GBp.

Beschreibung

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Corporate Governance

AstraZeneca PLCs ISS Governance QualityScore, Stand 1. Oktober 2022, lautet 4. Die grundlegenden Scores sind Audit: 3, Vorstand: 7, Shareholderrechte: 1, Kompensation: 1.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.